UK markets open in 2 hours 58 minutes

Orion Oyj (0M2N.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
35.25+0.05 (+0.14%)
At close: 04:45PM GMT
Full screen
Previous close35.20
Open35.25
Bid0.00 x 0
Ask0.00 x 0
Day's range35.25 - 35.25
52-week range35.25 - 35.25
Volume68
Avg. volumeN/A
Market cap4.523B
Beta (5Y monthly)0.60
PE ratio (TTM)26.56
EPS (TTM)1.33
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Orion Corporation and CuraTeQ Biologics expand their biosimilar distribution agreement in Europe

    ORION CORPORATION PRESS RELEASE 11 JANUARY 2022 at 8.00 EET Orion Corporation and CuraTeQ Biologics expand their biosimilar distribution agreement in Europe Orion Corporation (“Orion”) and CuraTeQ Biologics Private Limited (“CuraTeQ”), a wholly-owned subsidiary of Aurobindo Pharma Ltd., have expanded their biosimilar distribution agreement to the Baltic countries. The original marketing and distribution agreement signed in 2020 covered the Nordics, Austria, Hungary and Slovenia. Under the agreem

  • Globe Newswire

    102,428 Orion Corporation A shares converted into B shares

    ORION CORPORATION STOCK EXCHANGE RELEASE 10 DECEMBER 2021 at 9.00 EET 102,428 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 102,428 A shares have been converted into 102,428 B shares. The conversion has been entered into the Trade Register on 10 December 2021. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,813,206 A shares and 106,321,072 B shares. Th

  • Globe Newswire

    ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

    ORION CORPORATION STOCK EXCHANGE RELEASE / INSIDE INFORMATION3 DECEMBER 2021 at 8.30 EET ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer Orion’s and Bayer’s Phase III ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) comp